Vascular Ageing, Decline in Brain and Cognitive Functions

https://neurodegenerationresearch.eu/survey/vascular-ageing-decline-in-brain-and-cognitive-functions/

Title of cohort

Vascular Ageing, Decline in Brain and Cognitive Functions

Acronym for cohort

EVA

Name of Principal Investigator - Title

Dr

Name of Principal Investigator - First name

Claudine

Name of Principal Investigator - Last name

Berr

Address of institution -Institution

INSERM U888

Address of institution - Street address
Address of institution - City

MONTPELLIER

Address of institution - Postcode

34093

Country

France

Website
Contact email

claudine.berr@inserm.fr

Funding source

MERCK, EISAI

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Neurodegenerative disease in general

Q1b. When are studies on the above condition(s) expected to become possible?

Already possible

Q2a. In a single sentence what is the stated aim of the cohort?

To investigate vascular ageing, decline in brain and cognitive function and associated factors with a longitudinal follow-up study

Q2b. What distinguishes this cohort from other population cohorts?

Pre aging

Q3a. i) Number of publications that involve use of your cohort to date

33

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

http://www.ncbi.nlm.nih.gov/pubmed/?term=EVA+AND+Berr+C[Author]+OR+17130689[uid]

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

59

Q4a. Study criteria: what is the age range of participants at recruitment? To:

71

Q4b. Study criteria: what are the inclusion criteria?

Subjects from both genders born between 1922 and 1932 (59 to 71 years old at enrolment), included in electoral registers in Nantes, can speak French and living in Nantes.

Q4c. Study criteria: what are the exclusion criteria?
Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

1,000-5,000 participants

Q6a. Please describe what measures are used to characterise participants

Cognitive and vasular evaluation

Q6b. Are there additional measures for participants with a clinical disorder?

No

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

Yes

If yes please specify

Cognitive decline

Q7. What is the study design (select all that apply)?

Prospective cohort|Longitudinal

Q8. Are your cases matched by
Q9a. Does your study include a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describe

800 with MRI

Q10a. i) Please enter the data collection start date

01/07/1991

Q10a. ii) Please enter the data collection end date

01/07/1991

Q10a. iii) Is data collection for this study

Data analysis ongoing| Closed to new patients

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?
Q11. Is data collected

Only through the study

Other please specify here
Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

No

Q13a. Please give information on the format and availability of data stored in a database (1)

Data summarised in database

% available
Q13a. Please give information on the format and availability of data stored in a database (2)
% available
Q13a. Please give information on the format and availability of data stored in a database (3)
% available
Q13a. Please give information on the format and availability of data stored in a database (4)
% available
Other (please specify)
% available
Q13b. Please give information on the format and availability of data held as individual records (1)
% available
Q13b. Please give information on the format and availability of data held as individual records (2)
% available
Q13b. Please give information on the format and availability of data held as individual records (3)

Data held on computer based records

% available
Q13b. Please give information on the format and availability of data held as individual records (4)
% available
Please specify language used

French

Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource| Apply to PI or co-ordinator at resource

Q15. What data sharing policy is specified as a condition of use?

No policy exists

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below:

Living donors: blood| Living donors: blood derivatives| Living donors: DNA|

Q16b. ii) In what form are tissues/samples/DNA supplied?
Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Yes

Q17. Is information on biological characteristics available to other groups?

Yes, for all the cohort

Number of Patients
% of total cohort

Types:
Population Cohorts

Member States:
France

Diseases:
Neurodegenerative disease in general

Years:
2016

Database Categories:
N/A

Database Tags:
N/A